FDA Approves Abbott's Launch of Freenome's Blood-Based CRC Screening Test
Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test, received FDA approval and will be commercialized in the U.S. by Abbott to help millions of Americans who are overdue for screening.
View filing at SEC.gov →